JANX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 13333 min ago

@ $43.76

Išleistas: 24 geg. 2024 @ 17:30

Grąža: 22.27%

Ankstesnis signalas: geg. 23 - 19:50

Ankstesnis signalas: Pirkimas

Grąža: -2.20 %

Live Chart Being Loaded With Signals

Commentary (31 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	779 919
Vidutinė apimtis	771 358
Rinkos kapitalizacija	2.77B
EPS	$0 ( 2024-05-14 )
Kita pelno data	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-44.58
ATR14	$0.0940 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Ra Capital Management, L.p.	Buy	1 397 849	Pre-Funded Warrants (Right to Buy)
2024-02-29	Avalon Ventures Xi, L.p.	Sell	447 949	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	438 722	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	84 985	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Buy	31 456	Common Stock

INSIDER POWER
55.49
Last 96 transactions
Buy: 16 444 752 \| Sell: 7 280 818

Tūris Koreliacija

Ilgas: -0.16 (neutral)

Trumpas: -0.64 (weak negative)

Signal:(36.168) Neutral

Janux Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Janux Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

0.28
( neutral )

0.24
( neutral )

0.00
( neutral )

0.12
( neutral )

-0.11
( neutral )

0.29
( neutral )

Janux Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$8.08M
Bruto pelnas:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2023
Pajamos:	$8.08M
Bruto pelnas:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2022
Pajamos:	$8.61M
Bruto pelnas:	$7.77M (90.23 %)
EPS:	$-1.310

FY	2021
Pajamos:	$3.64M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.794

Financial Reports:

No articles found.

Janux Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company\'s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.